Share on StockTwits

Tornier NV (NASDAQ:TRNX)’s share price hit a new 52-week high during mid-day trading on Friday , reports. The stock traded as high as $24.35 and last traded at $24.30, with a volume of 330,071 shares changing hands. The stock had previously closed at $23.50.

TRNX has been the subject of a number of recent research reports. Analysts at TheStreet upgraded shares of Tornier NV from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. Separately, analysts at Barclays raised their price target on shares of Tornier NV from $23.00 to $26.00 in a research note on Thursday, June 5th. They now have an “overweight” rating on the stock. Finally, analysts at Summer Street upgraded shares of Tornier NV from a “sell” rating to a “neutral” rating in a research note on Wednesday, May 7th. They now have a $18.00 price target on the stock, up previously from $16.00. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $20.29.

The stock’s 50-day moving average is $21.21 and its 200-day moving average is $19.56. The company’s market cap is $1.171 billion.

Tornier NV (NASDAQ:TRNX) last released its earnings data on Tuesday, May 6th. The company reported ($0.11) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.14) by $0.03. The company had revenue of $89.00 million for the quarter, compared to the consensus estimate of $80.41 million. During the same quarter last year, the company posted ($0.17) earnings per share. Tornier NV’s revenue was up 7.6% compared to the same quarter last year. Analysts expect that Tornier NV will post $-0.45 EPS for the current fiscal year.

Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.